H1N1 convalescent plasma + oseltamivir

This is an investigational combination therapy consisting of convalescent plasma and the antiviral agent oseltamivir, developed by The University of Hong Kong for the treatment of severe pandemic influenza A (H1N1) 2009 virus infection. The convalescent plasma is harvested from recovered patients and contains high titers (≥1:160) of neutralizing antibodies that target the H1N1 virus. Oseltamivir is a small molecule neuraminidase inhibitor that prevents viral shedding. Clinical research indicated that the combination reduces respiratory viral load, serum cytokine response, and mortality in critically ill patients who show clinical deterioration despite standard antiviral treatment. This treatment was evaluated in a clinical research setting during the 2009 pandemic and is not a branded commercial product.

Other names

H1N1 convalescent plasma and oseltamivirH-1N1 convalescent plasma and oseltamivirH 1N1 convalescent plasma and oseltamivirconvalescent plasma and oseltamivir